Piper Jaffray Companies Increases Fluidigm (FLDM) Price Target to $14.00

Fluidigm (NASDAQ:FLDM) had its target price raised by Piper Jaffray Companies from $10.00 to $14.00 in a research note issued on Wednesday, The Fly reports. The firm currently has an “overweight” rating on the medical research company’s stock. Piper Jaffray Companies’ target price would indicate a potential upside of 1.38% from the stock’s previous close.

Several other equities analysts also recently weighed in on FLDM. BidaskClub raised Fluidigm from a “hold” rating to a “buy” rating in a research note on Tuesday, November 20th. Zacks Investment Research raised Fluidigm from a “hold” rating to a “buy” rating and set a $9.25 price objective for the company in a research note on Thursday, November 29th. ValuEngine raised Fluidigm from a “sell” rating to a “hold” rating in a research note on Wednesday, January 2nd. Finally, Janney Montgomery Scott raised Fluidigm from a “neutral” rating to a “buy” rating in a research note on Thursday, January 3rd. One analyst has rated the stock with a hold rating and five have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $14.00.

FLDM opened at $13.81 on Wednesday. The company has a quick ratio of 1.45, a current ratio of 1.85 and a debt-to-equity ratio of 7.56. The company has a market capitalization of $551.27 million, a PE ratio of -17.26 and a beta of 2.40. Fluidigm has a 12 month low of $4.65 and a 12 month high of $14.50.

Fluidigm (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, February 7th. The medical research company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.07. Fluidigm had a negative return on equity of 90.07% and a negative net margin of 52.24%. The firm had revenue of $32.33 million during the quarter, compared to the consensus estimate of $30.55 million. As a group, research analysts forecast that Fluidigm will post -0.71 EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Primecap Management Co. CA increased its stake in Fluidigm by 1.1% in the 3rd quarter. Primecap Management Co. CA now owns 5,856,043 shares of the medical research company’s stock valued at $43,862,000 after purchasing an additional 64,000 shares in the last quarter. Neuberger Berman Group LLC increased its position in Fluidigm by 0.5% during the third quarter. Neuberger Berman Group LLC now owns 4,535,180 shares of the medical research company’s stock worth $33,971,000 after buying an additional 24,186 shares in the last quarter. BlackRock Inc. increased its position in Fluidigm by 9.1% during the fourth quarter. BlackRock Inc. now owns 2,139,878 shares of the medical research company’s stock worth $18,445,000 after buying an additional 178,429 shares in the last quarter. Vanguard Group Inc increased its position in Fluidigm by 9.5% during the third quarter. Vanguard Group Inc now owns 1,410,526 shares of the medical research company’s stock worth $10,565,000 after buying an additional 121,815 shares in the last quarter. Finally, Vanguard Group Inc. increased its position in Fluidigm by 9.5% during the third quarter. Vanguard Group Inc. now owns 1,410,526 shares of the medical research company’s stock worth $10,565,000 after buying an additional 121,815 shares in the last quarter.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents. The company also provides preparatory instruments, such as access array and Juno systems; and analytical instruments comprising Biomark HD system and EP1 system.

Recommended Story: Is the Dow Jones Industrial Average (DJIA) still relevant?

The Fly

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit